First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. (Q39668193)

From Wikidata
Jump to: navigation, search
scientific article published on 11 August 2010
edit
Language Label Description Also known as
English
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
scientific article published on 11 August 2010

    Statements

    First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. (English)
    Fernanda Salazar
    Miguel Angel Molina
    Maria Sanchez-Ronco
    Teresa Moran
    Jose Luis Ramirez
    Jose Miguel Sanchez
    Rolf Stahel
    Pilar Garrido
    Manuel Cobo
    Dolores Isla
    Jordi Bertran-Alamillo
    Bartomeu Massuti
    Felipe Cardenal
    Christian Manegold
    Pilar Lianes
    Jose Manuel Trigo
    Jose Javier Sanchez
    Miquel Taron
    Rafael Rosell
    11 August 2010
    84-91

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit